Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice

Tangying Lu, Rupal Ramakrishnan, Soner Altiok, Je In Youn, Pingyan Cheng, Esteban Celis, Vladimir Pisarev, Simon Sherman, Michael B. Sporn, Dmitry Gabrilovich

Research output: Contribution to journalArticle

177 Citations (Scopus)

Abstract

Cancer immunotherapeutic approaches induce tumor-specific immune responses, in particular CTL responses, in many patients treated. However, such approaches are clinically beneficial to only a few patients. We set out to investigate one possible explanation for the failure of CTLs to eliminate tumors, specifically, the concept that this failure is not dependent on inhibition of T cell function. In a previous study, we found that in mice, myeloid-derived suppressor cells (MDSCs) are a source of the free radical peroxynitrite (PNT). Here, we show that pretreatment of mouse and human tumor cells with PNT or with MDSCs inhibits binding of processed peptides to tumor cell-associated MHC, and as a result, tumor cells become resistant to antigen-specific CTLs. This effect was abrogated in MDSCs treated with a PNT inhibitor. In a mouse model of tumor-associated inflammation in which the antitumor effects of antigen-specific CTLs are eradicated by expression of IL-1β in the tumor cells, we determined that therapeutic failure was not caused by more profound suppression of CTLs by IL-1β-expressing tumors than tumors not expressing this proinflammatory cytokine. Rather, therapeutic failure was a result of the presence of PNT. Clinical relevance for these data was suggested by the observation that myeloid cells were the predominant source of PNT in human lung, pancreatic, and breast cancer samples. Our data therefore suggest what we believe to be a novel mechanism of MDSC-mediated tumor cell resistance to CTLs.

Original languageEnglish (US)
Pages (from-to)4015-4029
Number of pages15
JournalJournal of Clinical Investigation
Volume121
Issue number10
DOIs
StatePublished - Oct 3 2011

Fingerprint

Myeloid Cells
T-Lymphocytes
Peroxynitrous Acid
Neoplasms
Interleukin-1
Antigens
Pancreatic Neoplasms
Free Radicals
Lung Neoplasms
Breast Neoplasms
Cytokines
Inflammation
Peptides

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lu, T., Ramakrishnan, R., Altiok, S., Youn, J. I., Cheng, P., Celis, E., ... Gabrilovich, D. (2011). Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. Journal of Clinical Investigation, 121(10), 4015-4029. https://doi.org/10.1172/JCI45862

Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. / Lu, Tangying; Ramakrishnan, Rupal; Altiok, Soner; Youn, Je In; Cheng, Pingyan; Celis, Esteban; Pisarev, Vladimir; Sherman, Simon; Sporn, Michael B.; Gabrilovich, Dmitry.

In: Journal of Clinical Investigation, Vol. 121, No. 10, 03.10.2011, p. 4015-4029.

Research output: Contribution to journalArticle

Lu, T, Ramakrishnan, R, Altiok, S, Youn, JI, Cheng, P, Celis, E, Pisarev, V, Sherman, S, Sporn, MB & Gabrilovich, D 2011, 'Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice', Journal of Clinical Investigation, vol. 121, no. 10, pp. 4015-4029. https://doi.org/10.1172/JCI45862
Lu, Tangying ; Ramakrishnan, Rupal ; Altiok, Soner ; Youn, Je In ; Cheng, Pingyan ; Celis, Esteban ; Pisarev, Vladimir ; Sherman, Simon ; Sporn, Michael B. ; Gabrilovich, Dmitry. / Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. In: Journal of Clinical Investigation. 2011 ; Vol. 121, No. 10. pp. 4015-4029.
@article{13284169dd50414fa2280d8a9cbb3baa,
title = "Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice",
abstract = "Cancer immunotherapeutic approaches induce tumor-specific immune responses, in particular CTL responses, in many patients treated. However, such approaches are clinically beneficial to only a few patients. We set out to investigate one possible explanation for the failure of CTLs to eliminate tumors, specifically, the concept that this failure is not dependent on inhibition of T cell function. In a previous study, we found that in mice, myeloid-derived suppressor cells (MDSCs) are a source of the free radical peroxynitrite (PNT). Here, we show that pretreatment of mouse and human tumor cells with PNT or with MDSCs inhibits binding of processed peptides to tumor cell-associated MHC, and as a result, tumor cells become resistant to antigen-specific CTLs. This effect was abrogated in MDSCs treated with a PNT inhibitor. In a mouse model of tumor-associated inflammation in which the antitumor effects of antigen-specific CTLs are eradicated by expression of IL-1β in the tumor cells, we determined that therapeutic failure was not caused by more profound suppression of CTLs by IL-1β-expressing tumors than tumors not expressing this proinflammatory cytokine. Rather, therapeutic failure was a result of the presence of PNT. Clinical relevance for these data was suggested by the observation that myeloid cells were the predominant source of PNT in human lung, pancreatic, and breast cancer samples. Our data therefore suggest what we believe to be a novel mechanism of MDSC-mediated tumor cell resistance to CTLs.",
author = "Tangying Lu and Rupal Ramakrishnan and Soner Altiok and Youn, {Je In} and Pingyan Cheng and Esteban Celis and Vladimir Pisarev and Simon Sherman and Sporn, {Michael B.} and Dmitry Gabrilovich",
year = "2011",
month = "10",
day = "3",
doi = "10.1172/JCI45862",
language = "English (US)",
volume = "121",
pages = "4015--4029",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "10",

}

TY - JOUR

T1 - Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice

AU - Lu, Tangying

AU - Ramakrishnan, Rupal

AU - Altiok, Soner

AU - Youn, Je In

AU - Cheng, Pingyan

AU - Celis, Esteban

AU - Pisarev, Vladimir

AU - Sherman, Simon

AU - Sporn, Michael B.

AU - Gabrilovich, Dmitry

PY - 2011/10/3

Y1 - 2011/10/3

N2 - Cancer immunotherapeutic approaches induce tumor-specific immune responses, in particular CTL responses, in many patients treated. However, such approaches are clinically beneficial to only a few patients. We set out to investigate one possible explanation for the failure of CTLs to eliminate tumors, specifically, the concept that this failure is not dependent on inhibition of T cell function. In a previous study, we found that in mice, myeloid-derived suppressor cells (MDSCs) are a source of the free radical peroxynitrite (PNT). Here, we show that pretreatment of mouse and human tumor cells with PNT or with MDSCs inhibits binding of processed peptides to tumor cell-associated MHC, and as a result, tumor cells become resistant to antigen-specific CTLs. This effect was abrogated in MDSCs treated with a PNT inhibitor. In a mouse model of tumor-associated inflammation in which the antitumor effects of antigen-specific CTLs are eradicated by expression of IL-1β in the tumor cells, we determined that therapeutic failure was not caused by more profound suppression of CTLs by IL-1β-expressing tumors than tumors not expressing this proinflammatory cytokine. Rather, therapeutic failure was a result of the presence of PNT. Clinical relevance for these data was suggested by the observation that myeloid cells were the predominant source of PNT in human lung, pancreatic, and breast cancer samples. Our data therefore suggest what we believe to be a novel mechanism of MDSC-mediated tumor cell resistance to CTLs.

AB - Cancer immunotherapeutic approaches induce tumor-specific immune responses, in particular CTL responses, in many patients treated. However, such approaches are clinically beneficial to only a few patients. We set out to investigate one possible explanation for the failure of CTLs to eliminate tumors, specifically, the concept that this failure is not dependent on inhibition of T cell function. In a previous study, we found that in mice, myeloid-derived suppressor cells (MDSCs) are a source of the free radical peroxynitrite (PNT). Here, we show that pretreatment of mouse and human tumor cells with PNT or with MDSCs inhibits binding of processed peptides to tumor cell-associated MHC, and as a result, tumor cells become resistant to antigen-specific CTLs. This effect was abrogated in MDSCs treated with a PNT inhibitor. In a mouse model of tumor-associated inflammation in which the antitumor effects of antigen-specific CTLs are eradicated by expression of IL-1β in the tumor cells, we determined that therapeutic failure was not caused by more profound suppression of CTLs by IL-1β-expressing tumors than tumors not expressing this proinflammatory cytokine. Rather, therapeutic failure was a result of the presence of PNT. Clinical relevance for these data was suggested by the observation that myeloid cells were the predominant source of PNT in human lung, pancreatic, and breast cancer samples. Our data therefore suggest what we believe to be a novel mechanism of MDSC-mediated tumor cell resistance to CTLs.

UR - http://www.scopus.com/inward/record.url?scp=80053421470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053421470&partnerID=8YFLogxK

U2 - 10.1172/JCI45862

DO - 10.1172/JCI45862

M3 - Article

VL - 121

SP - 4015

EP - 4029

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 10

ER -